New PET imaging for kidney cancer diagnosis
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new kind of PET scan that might better detect kidney cancer. It involves an injection of a special imaging agent and a scan to see if the cancer shows up clearly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have suspected or confirmed kidney cancer, based on tests like ultrasound, CT, or biopsy.
- You are in generally good health.
- You can lie still for a PET scan (no severe claustrophobia).
- You are not pregnant or breastfeeding.
- If you could become pregnant, you agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a special PET scan (using a radioactive tracer called rubidium-82) can help doctors better understand how aggressive a kidney cancer is before surgery. If you have a medium-sized kidney tumor that looks like clear cell cancer and you are scheduled for surgery, you may be able to join.
This Phase 1 study tests whether a special PET/CT scan drug ([18F]PT2385) can help doctors see kidney cancer and related tumors. It may help guide diagnosis and treatment decisions, especially in people planning surgery or starting belzutifan.
This trial tests a new PET/CT scan that uses a special tracer to find clear cell kidney cancer. If you are scheduled for kidney tumor removal, this scan may help your surgeon see the cancer more clearly before surgery.
This study tests a new type of PET scan that uses a tracer called 68Ga-RCCB6 to see kidney cancer more clearly. It compares this scan to another PET scan (68Ga-PSMA) to help doctors stage the cancer, check treatment response, and detect any return of the disease.
This early-stage trial tests a new type of imaging scan (called PET) that uses a special tracer to help doctors see tumors better. The scan targets a protein called CAIX that appears on many cancer cells, which may help with accurate diagnosis and staging.
This trial is testing a new imaging agent called 18F-NY104 to see if it can help doctors see kidney cancer tumors on a PET/CT scan. If you have known or suspected kidney cancer that has spread or come back, this study may help find out if the tracer works for you.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.